US StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

Q32 Bio Inc.

1.55

-0.0100-0.64%

Volume:78.07K

Turnover:120.09K

Market Cap:18.91M

PE:-0.24

High:1.62

Open:1.61

Low:1.49

Close:1.56

Loading ...

Overview Company News Filings

Press Release: Q32 Bio Appoints Adrien Sipos, M.D., Ph.D., as Interim Chief Medical Officer

Q32 Bio Appoints Adrien Sipos, M.d., Ph.d., as Interim Chief Medical Officer

THOMSON REUTERS

Q32 Bio Inc. Concluded Annual Stockholder Meeting

Q32 Bio Inc. Receives Nasdaq Notice for Non-Compliance with Listing Requirements Due to Stockholders' Equity Deficit

Q32 Bio Inc reports results for the quarter ended March 31 - Earnings Summary

BRIEF-Q32 Bio Reports First Quarter 2025 Financial Results And Provides Corporate Update

Q32 Bio Q1 2025 EPS $(0.90) Up From $(6.33) YoY, Cash And Cash Equivalents Of $65.5M As Of March 31, 2025 Expected To Provide Financial Runway Into 2H 2026

Q32 Bio Reports First Quarter 2025 Financial Results and Provides Corporate Update

THOMSON REUTERS

Q32 Bio Inc - Q1 Net Loss per Share $0.90

THOMSON REUTERS

Q32 Bio Inc expected to post a loss of $1.23 a share - Earnings Preview

Q32 Bio granted Fast Track designation for bempikibart

BRIEF-Q32 Bio Announces FDA Fast Track Designation Granted To Bempikibart (ADX-914) For The Treatment Of Alopecia Areata

Q32 Bio Announces FDA Fast Track Designation Granted to Bempikibart (ADX-914) for the Treatment of Alopecia Areata

BRIEF-Q32 Bio Inc - Mark Iwicki Resigns From Q32 Bio Board Effective Dec 31, 2025

Q32 Bio Inc - Iwicki Resigns to Focus on CEO Role at Inhibikase Therapeutics

THOMSON REUTERS

Q32 Bio Inc - Mark Iwicki Resigns From Q32 Bio Board Effective Dec 31, 2025

THOMSON REUTERS

BRIEF-Q32 Bio Doses First Patients In Both Part A Open-Label Extension And Part B Of Signal-Aa Phase 2A Trial

Q32 Bio Inc - Expects Signal-Aa Part B Data in 1H'26

THOMSON REUTERS

Q32 Bio Doses First Patients in Both Part a Open-Label Extension and Part B of Signal-Aa Phase 2a Trial Evaluating Bempikibart in Alopecia Areata

THOMSON REUTERS

BRIEF-Q32 Bio Files For Mixed Shelf Of Up To $200 Million - SEC Filing

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/QTTB/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"QTTB","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"QTTB\",,,,,undefined,":{"symbol":"QTTB","market":"US","secType":"STK","nameCN":"Q32 Bio Inc.","latestPrice":1.55,"timestamp":1750968000000,"preClose":1.56,"halted":0,"volume":78071,"delay":0,"floatShares":4728923,"shares":12197615,"eps":-6.578484,"marketStatus":"Pre-Mkt","change":-0.01,"latestTime":"06-27 06:34:52 EDT","open":1.61,"high":1.618,"low":1.49,"amount":120094.4801546,"amplitude":0.082051,"askPrice":1.81,"askSize":100,"bidPrice":1.38,"bidSize":100,"shortable":3,"etf":0,"ttmEps":-6.578484,"tradingStatus":1,"nextMarketStatus":{"tag":"Open","tradingStatus":2,"beginTime":1751031000000},"marketStatusCode":1,"adr":0,"listingDate":1522209600000,"exchange":"NASDAQ","adjPreClose":1.55,"postHourTrading":{"tag":"盘后","latestPrice":1.52,"preClose":1.55,"latestTime":"17:26 EDT","volume":260,"amount":396.04,"timestamp":1750973186561},"volumeRatio":1.1138392799807333,"impliedVol":0.4864,"impliedVolPercentile":0.3443},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"QTTB\",,,,,undefined,":{"symbol":"QTTB","floatShares":4728923,"roa":"-33.80%","roe":"-267.20%","lyrEps":-5.12108,"volumeRatio":1.1138392799807333,"shares":12197615,"dividePrice":0,"high":1.618,"amplitude":0.082051,"preClose":1.56,"low":1.49,"week52Low":1.38,"pbRate":"-4.71","psRate":"-1.29","week52High":53.79,"institutionHeld":0,"latestPrice":1.55,"eps":-6.578484,"divideRate":0,"volume":78071,"delay":0,"ttmEps":-6.578484,"open":1.61,"prevYearClose":3.44,"prevWeekClose":1.55,"prevMonthClose":1.73,"prevQuarterClose":1.65,"fiveDayClose":1.595,"twentyDayClose":1.83,"sixtyDayClose":1.65},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"QTTB\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2546110862","title":"Press Release: Q32 Bio Appoints Adrien Sipos, M.D., Ph.D., as Interim Chief Medical Officer","url":"https://stock-news.laohu8.com/highlight/detail?id=2546110862","media":"Dow Jones","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2546110862?lang=en_us&edition=fundamental","pubTime":"2025-06-25 18:59","pubTimestamp":1750849140,"startTime":"0","endTime":"0","summary":"-- Dr. Sipos is an immunologist and seasoned Immunology and Inflammation (I&I) drug developer, with over 25 years of clinical development and medical affairs leadership experience --. Prior to joining Q32 Bio, Dr. Sipos served as President and Chief Medical Officer at PRAXICO Inc., where she advised both large and emerging biopharmaceutical companies on clinical development and medical affairs initiatives across multiple therapeutic areas and development stages. Prior to PRAXICO, Dr. Sipos was Head of Immunology, Late-Stage Clinical Development at Biogen, Inc., where she established the global clinical development organization for late-stage immunology and oversaw development and regulatory activities for multiple mid- to late-stage programs. Earlier, Dr. Sipos held clinical development and medical affairs roles of increasing responsibility, with an emphasis on immunology, at Sanofi Genzyme and Eli Lilly. Dr. Sipos completed postdoctoral research at the University of Oxford, Linacre Co","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"Press Release: Q32 Bio Appoints Adrien Sipos, M.D., Ph.D., as Interim Chief Medical Officer","news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","QTTB"],"gpt_icon":0},{"id":"2546211449","title":"Q32 Bio Appoints Adrien Sipos, M.d., Ph.d., as Interim Chief Medical Officer","url":"https://stock-news.laohu8.com/highlight/detail?id=2546211449","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2546211449?lang=en_us&edition=fundamental","pubTime":"2025-06-25 18:59","pubTimestamp":1750849144,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250625:nTUA7NH9WH:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","QTTB"],"gpt_icon":0},{"id":"2544901969","title":"Q32 Bio Inc. Concluded Annual Stockholder Meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2544901969","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2544901969?lang=en_us&edition=fundamental","pubTime":"2025-06-18 04:02","pubTimestamp":1750190573,"startTime":"0","endTime":"0","summary":"Q32 Bio Inc. held its Annual Meeting of Stockholders on June 13, 2025. During the meeting, stockholders approved an amendment to the Company's Restated Certificate of Incorporation to limit the liability of certain officers. Additionally, stockholders elected David Grayzel, M.D., Isaac Manke, Ph.D., and Diyong Xu as Class I directors. Stockholders also voted for \"One Year\" as the preferred frequency of future advisory votes on executive compensation.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Q32 Bio Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on June 17, 2025, and is solely res","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250617:nNDLbR8L1F:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["QTTB","BK4139"],"gpt_icon":0},{"id":"2537338771","title":"Q32 Bio Inc. Receives Nasdaq Notice for Non-Compliance with Listing Requirements Due to Stockholders' Equity Deficit","url":"https://stock-news.laohu8.com/highlight/detail?id=2537338771","media":"Reuters","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2537338771?lang=en_us&edition=fundamental","pubTime":"2025-05-23 19:01","pubTimestamp":1747998062,"startTime":"0","endTime":"0","summary":"Q32 Bio Inc. has announced that it received a notice from the Nasdaq Stock Market LLC on May 19, 2025, indicating that the company is no longer in compliance with the minimum stockholders' equity requirement of $2.5 million for continued listing on the Nasdaq Capital Market. The company's recent financial report showed a stockholders' equity deficit of approximately $4.0 million. Additionally, Q32 Bio failed to meet alternative criteria, such as a market value of listed securities of $35.0 million or net income from continuing operations of $0.5 million. This situation arose partly due to the accounting impact of re-acquiring bempikibart from Amgen Inc. Q32 Bio now has 45 days to submit a compliance plan to Nasdaq. If accepted, Nasdaq may grant an extension of up to 180 days for Q32 Bio to meet the listing requirements. Meanwhile, the company's stock will continue trading on Nasdaq under the symbol \"QTTB.\"","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250523:nNDL29PMRQ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4534","LU2112291526.USD","SG9999001440.SGD","BK4139","LU0109394709.USD","BK4588","LU2242646821.SGD","LU2468319806.SGD","BK4566","LU2089984988.USD","IE00B2B36J28.USD","IE00BFTCPJ56.SGD","LU1983299246.USD","BK4585","LU0868494617.USD","LU1057294990.SGD","LU2242652126.USD","LU0889565916.HKD","IE00BJJMRZ35.SGD","BK4599","BK4533","LU1023059063.AUD","IE00B4R5TH58.HKD","BK4581","LU0122379950.USD","AMGN","IE0009355771.USD","QTTB","IE0002141913.USD","IE00BJT1NW94.SGD","LU0320765992.SGD","LU1061106388.HKD","LU0289739699.SGD","LU1571399168.USD","LU0058720904.USD"],"gpt_icon":0},{"id":"2533808731","title":"Q32 Bio Inc reports results for the quarter ended March 31 - Earnings Summary","url":"https://stock-news.laohu8.com/highlight/detail?id=2533808731","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2533808731?lang=en_us&edition=fundamental","pubTime":"2025-05-08 20:54","pubTimestamp":1746708894,"startTime":"0","endTime":"0","summary":"Q32 Bio Inc reports results for the quarter ended March 31 - Earnings SummaryQ32 Bio Inc QTTB.OQ reported a quarterly adjusted loss of 90 cents per share for the quarter ended March 31, higher than th","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250508:nL8N3RG1QB:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["QTTB"],"gpt_icon":0},{"id":"2533185298","title":"BRIEF-Q32 Bio Reports First Quarter 2025 Financial Results And Provides Corporate Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2533185298","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2533185298?lang=en_us&edition=fundamental","pubTime":"2025-05-08 19:25","pubTimestamp":1746703544,"startTime":"0","endTime":"0","summary":"BRIEF-Q32 Bio Reports First Quarter 2025 Financial Results And Provides Corporate UpdateMay 8 (Reuters) - Q32 Bio Inc QTTB.O:Q32 BIO REPORTS FIRST QUARTER 2025 FINANCIAL RESULTS AND PROVIDES CORPORATE","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250508:nTUA9TGWGH:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["QTTB","BK4139"],"gpt_icon":0},{"id":"2533183515","title":"Q32 Bio Q1 2025 EPS $(0.90) Up From $(6.33) YoY, Cash And Cash Equivalents Of $65.5M As Of March 31, 2025 Expected To Provide Financial Runway Into 2H 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2533183515","media":"Benzinga","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2533183515?lang=en_us&edition=fundamental","pubTime":"2025-05-08 19:08","pubTimestamp":1746702510,"startTime":"0","endTime":"0","summary":"Q32 Bio Q1 2025 EPS $(0.90) Up From $(6.33) YoY, Cash And Cash Equivalents Of $65.5M As Of March 31, 2025 Expected To Provide Financial Runway Into 2H 2026","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/25/05/45281259/q32-bio-q1-2025-eps-0-90-up-from-6-33-yoy-cash-and-cash-equivalents-of-65-5m-as-of-march-31-2025-ex","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["QTTB"],"gpt_icon":0},{"id":"2533900794","title":"Q32 Bio Reports First Quarter 2025 Financial Results and Provides Corporate Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2533900794","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2533900794?lang=en_us&edition=fundamental","pubTime":"2025-05-08 18:59","pubTimestamp":1746701948,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250508:nTUA9TGWGH:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","QTTB"],"gpt_icon":0},{"id":"2533183480","title":"Q32 Bio Inc - Q1 Net Loss per Share $0.90","url":"https://stock-news.laohu8.com/highlight/detail?id=2533183480","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2533183480?lang=en_us&edition=fundamental","pubTime":"2025-05-08 18:59","pubTimestamp":1746701948,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250508:nTUA9TGWGH:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","QTTB"],"gpt_icon":0},{"id":"2533581249","title":"Q32 Bio Inc  expected to post a loss of $1.23 a share - Earnings Preview","url":"https://stock-news.laohu8.com/highlight/detail?id=2533581249","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2533581249?lang=en_us&edition=fundamental","pubTime":"2025-05-05 20:55","pubTimestamp":1746449705,"startTime":"0","endTime":"0","summary":"Q32 Bio Inc  expected to post a loss of $1.23 a share - Earnings Preview Q32 Bio Inc QTTB.OQ QTTB.O is expected to show no change in quarterly revenue when it reports  results on May 7 (estimated) for","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250505:nL8N3RD11T:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["QTTB"],"gpt_icon":0},{"id":"2531033277","title":"Q32 Bio granted Fast Track designation for bempikibart","url":"https://stock-news.laohu8.com/highlight/detail?id=2531033277","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2531033277?lang=en_us&edition=fundamental","pubTime":"2025-04-30 19:21","pubTimestamp":1746012083,"startTime":"0","endTime":"0","summary":"Q32 Bio (QTTB) announced that the FDA has granted Fast Track designation to Q32 Bio’s bempikibart for the treatment of AA. Bempikibart is a fully h...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/q32-bio-granted-fast-track-designation-for-bempikibart?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/q32-bio-granted-fast-track-designation-for-bempikibart?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4585","QTTB","BK4153","AA","BK4139","IE00BFXG0V08.USD","FAST","BK4588","IE00B5TLWC47.USD","BK4104","IE00BYQQ9H92.USD","BK4567"],"gpt_icon":0},{"id":"2531338000","title":"BRIEF-Q32 Bio Announces FDA Fast Track Designation Granted To Bempikibart (ADX-914) For The Treatment Of Alopecia Areata","url":"https://stock-news.laohu8.com/highlight/detail?id=2531338000","media":"Reuters","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2531338000?lang=en_us&edition=fundamental","pubTime":"2025-04-30 19:17","pubTimestamp":1746011843,"startTime":"0","endTime":"0","summary":"BRIEF-Q32 Bio Announces FDA Fast Track Designation Granted To Bempikibart (ADX-914) For The Treatment Of Alopecia AreataApril 30 (Reuters) - Q32 Bio Inc QTTB.O:Q32 BIO ANNOUNCES FDA FAST TRACK DESIGNA","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250430:nTUA6R50WJ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["QTTB","BK4139"],"gpt_icon":0},{"id":"2531038831","title":"Q32 Bio Announces FDA Fast Track Designation Granted to Bempikibart (ADX-914) for the Treatment of Alopecia Areata","url":"https://stock-news.laohu8.com/highlight/detail?id=2531038831","media":"PR Newswire","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2531038831?lang=en_us&edition=fundamental","pubTime":"2025-04-30 18:59","pubTimestamp":1746010740,"startTime":"0","endTime":"0","summary":"WALTHAM, Mass., April 30, 2025 /PRNewswire/ -- Q32 Bio Inc.  , a clinical stage biotechnology company focused on developing innovative therapies for alopecia areata  and other autoimmune and inflammatory diseases, today announced that the United States Food and Drug Administration  has granted Fast Track designation  to Q32 Bio's bempikibart  for the treatment of AA. Bempikibart is a fully human anti-IL-7Rα antibody that re-regulates adaptive immune function by blocking IL-7 and TSLP signaling that is in development for the treatment of AA and currently being evaluated in a Phase 2 program.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"yahoofinance","url":"https://finance.yahoo.com/news/q32-bio-announces-fda-fast-105900537.html","rn_cache_url":null,"customStyle":"img, svg { display: none !important; }","selectors":"article","filters":"","directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/q32-bio-announces-fda-fast-105900537.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["IE00B5TLWC47.USD","ADX","BK4567","AA","IE00BFXG0V08.USD","BK4588","QTTB","FAST","IE00BYQQ9H92.USD","BK4139","BK4153","BK4585","BK4104"],"gpt_icon":0},{"id":"2530319849","title":"BRIEF-Q32 Bio Inc - Mark Iwicki Resigns From Q32 Bio Board Effective Dec 31, 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2530319849","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2530319849?lang=en_us&edition=fundamental","pubTime":"2025-04-26 04:54","pubTimestamp":1745614493,"startTime":"0","endTime":"0","summary":"BRIEF-Q32 Bio Inc - Mark Iwicki Resigns From Q32 Bio Board Effective Dec 31, 2025April 25  - Inhibikase Therapeutics Inc IKT.O:Q32 BIO INC - MARK IWICKI RESIGNS FROM Q32 BIO BOARD EFFECTIVE DEC 31, 2025Q32 BIO INC - IWICKI RESIGNS TO FOCUS ON CEO ROLE AT INHIBIKASE THERAPEUTICSSource text: [ID:n0001193125-25-096703]Further company coverage: IKT.O ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250425:nFWN3R32JR:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["QTTB","BK4139","IKT"],"gpt_icon":0},{"id":"2530167977","title":"Q32 Bio Inc - Iwicki Resigns to Focus on CEO Role at Inhibikase Therapeutics","url":"https://stock-news.laohu8.com/highlight/detail?id=2530167977","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2530167977?lang=en_us&edition=fundamental","pubTime":"2025-04-26 04:05","pubTimestamp":1745611541,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250425:nFWN3R32JR:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["QTTB","IKT","BK4139"],"gpt_icon":0},{"id":"2530167971","title":"Q32 Bio Inc - Mark Iwicki Resigns From Q32 Bio Board Effective Dec 31, 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2530167971","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2530167971?lang=en_us&edition=fundamental","pubTime":"2025-04-26 04:05","pubTimestamp":1745611541,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250425:nFWN3R32JR:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["IKT","QTTB","BK4139"],"gpt_icon":0},{"id":"2527294200","title":"BRIEF-Q32 Bio Doses First Patients In Both Part A Open-Label Extension And Part B Of Signal-Aa Phase 2A Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2527294200","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2527294200?lang=en_us&edition=fundamental","pubTime":"2025-04-16 19:07","pubTimestamp":1744801647,"startTime":"0","endTime":"0","summary":"BRIEF-Q32 Bio Doses First Patients In Both Part A Open-Label Extension And Part B Of Signal-Aa Phase 2A TrialApril 16 (Reuters) - Q32 Bio Inc QTTB.O:Q32 BIO DOSES FIRST PATIENTS IN BOTH PART A OPEN-LA","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250416:nTUA48LMKQ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["QTTB","BK4139"],"gpt_icon":0},{"id":"2527993291","title":"Q32 Bio Inc - Expects Signal-Aa Part B Data in 1H'26","url":"https://stock-news.laohu8.com/highlight/detail?id=2527993291","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2527993291?lang=en_us&edition=fundamental","pubTime":"2025-04-16 18:59","pubTimestamp":1744801142,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250416:nTUA48LMKQ:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["QTTB","BK4139"],"gpt_icon":0},{"id":"2527939291","title":"Q32 Bio Doses First Patients in Both Part a Open-Label Extension and Part B of Signal-Aa Phase 2a Trial Evaluating Bempikibart in Alopecia Areata","url":"https://stock-news.laohu8.com/highlight/detail?id=2527939291","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2527939291?lang=en_us&edition=fundamental","pubTime":"2025-04-16 18:59","pubTimestamp":1744801142,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250416:nTUA48LMKQ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["QTTB","BK4139"],"gpt_icon":0},{"id":"2526614647","title":"BRIEF-Q32 Bio Files For Mixed Shelf Of Up To $200 Million - SEC Filing","url":"https://stock-news.laohu8.com/highlight/detail?id=2526614647","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2526614647?lang=en_us&edition=fundamental","pubTime":"2025-04-12 05:53","pubTimestamp":1744408384,"startTime":"0","endTime":"0","summary":"BRIEF-Q32 Bio Files For Mixed Shelf Of Up To $200 Million - SEC FilingApril 11 (Reuters) - Q32 Bio Inc QTTB.O:Q32 BIO FILES FOR MIXED SHELF OF UP TO $200 MILLION - SEC FILINGSource text: [ID:n0001193125-25-079136]Further company coverage: QTTB.O ((Reuters.Briefs@thomsonreuters.com;))","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250411:nFWN3QP11I:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["QTTB","BK4139"],"gpt_icon":0}],"pageSize":20,"totalPage":3,"pageCount":1,"totalSize":45,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/QTTB\",params:#limit:5,,,undefined,":[{"market":"US","date":"2025-03-11","symbol":"QTTB","fiscalQuarterEnding":"2024/12","expectedEps":-1.49,"name":null,"time":"Pre-Market","type":"earning","dateTimestamp":1741665600000,"reportTimeType":"pre","actualEps":-1.16},{"market":"US","date":"2024-05-09","symbol":"QTTB","fiscalQuarterEnding":"2024/03","expectedEps":-1.42,"name":null,"time":"Pre-Market","type":"earning","dateTimestamp":1715227200000,"reportTimeType":"pre","actualEps":-13.15},{"market":"US","date":"2024-03-26","symbol":"QTTB","defaultRemindTime":1711459800000,"type":"split","dateTimestamp":1711425600000,"forFactor":18,"toFactor":1,"ratio":18},{"market":"US","date":"2024-03-13","symbol":"QTTB","fiscalQuarterEnding":null,"expectedEps":null,"name":null,"time":"Pre-Market","type":"earning","dateTimestamp":1710302400000,"reportTimeType":"pre","actualEps":null},{"market":"US","date":"2023-11-14","symbol":"QTTB","fiscalQuarterEnding":"2023/09","expectedEps":-0.42,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1699938000000,"reportTimeType":"post","actualEps":-0.57}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"QTTB\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"QTTB\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0.25,"buy":0,"hold":0.75,"sell":0,"strongSell":0,"meanLabel":"BUY","meanPercent":0,"analysts":4,"updateTime":1739332800000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/QTTB\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"QTTB","date":"2025-06-26","current":-0.318236,"percent":0.986301,"low":-10.694771,"twenty":-8.282264,"median":-4.754675,"eighty":-0.469026,"high":-0.312116,"avg":-4.210601,"sd":3.702132,"marketCap":19028279},"quantilePoints":[{"date":"2024-04-05","current":-4.597074,"twenty":-4.75645,"median":-4.597074,"eighty":-3.952906,"marketCap":247060524},{"date":"2024-04-12","current":-5.285192,"twenty":-4.79019,"median":-4.726928,"eighty":-4.38975,"marketCap":284042061},{"date":"2024-04-19","current":-5.411717,"twenty":-5.438798,"median":-4.767993,"eighty":-4.57532,"marketCap":290841892},{"date":"2024-04-26","current":-6.268535,"twenty":-5.702502,"median":-5.138689,"eighty":-4.700069,"marketCap":336889870},{"date":"2024-05-03","current":-5.72026,"twenty":-5.938238,"median":-5.411717,"eighty":-4.727594,"marketCap":307423936},{"date":"2024-05-10","current":-5.948893,"twenty":-5.966207,"median":-5.603724,"eighty":-4.749348,"marketCap":319711350},{"date":"2024-05-17","current":-6.881182,"twenty":-6.171755,"median":-5.72026,"eighty":-4.765329,"marketCap":369815368},{"date":"2024-05-24","current":-6.526024,"twenty":-6.419477,"median":-5.852334,"eighty":-4.856783,"marketCap":350728123},{"date":"2024-05-31","current":-7.119566,"twenty":-6.557988,"median":-5.896729,"eighty":-4.946904,"marketCap":326617228},{"date":"2024-06-07","current":-5.417118,"twenty":-6.655355,"median":-5.948893,"eighty":-5.16799,"marketCap":248515704},{"date":"2024-06-14","current":-5.122964,"twenty":-6.625166,"median":-5.89118,"eighty":-5.079231,"marketCap":235021098},{"date":"2024-06-21","current":-4.172821,"twenty":-6.589953,"median":-5.833467,"eighty":-4.901621,"marketCap":191432327},{"date":"2024-06-28","current":-3.969777,"twenty":-6.557988,"median":-5.738018,"eighty":-4.86516,"marketCap":182117467},{"date":"2024-07-05","current":-4.511228,"twenty":-6.526024,"median":-5.680305,"eighty":-4.760002,"marketCap":206957095},{"date":"2024-07-12","current":-5.841429,"twenty":-6.49406,"median":-5.603724,"eighty":-4.798567,"marketCap":267981374},{"date":"2024-07-15","current":-6.825412,"twenty":-6.526024,"median":-5.660327,"eighty":-4.813855,"marketCap":313122622},{"date":"2024-08-02","current":-9.884093,"twenty":-6.542006,"median":-5.670316,"eighty":-4.829142,"marketCap":453442638},{"date":"2024-08-09","current":-7.500596,"twenty":-6.710706,"median":-5.738018,"eighty":-4.87207,"marketCap":427886482},{"date":"2024-08-16","current":-7.75207,"twenty":-6.825412,"median":-5.856316,"eighty":-4.928392,"marketCap":442232352},{"date":"2024-08-23","current":-8.155846,"twenty":-7.24299,"median":-5.902278,"eighty":-4.94491,"marketCap":465266543},{"date":"2024-08-30","current":-8.295371,"twenty":-7.548702,"median":-6.028804,"eighty":-4.98294,"marketCap":473226002},{"date":"2024-09-06","current":-9.684274,"twenty":-7.772364,"median":-6.120922,"eighty":-4.998807,"marketCap":552458796},{"date":"2024-09-13","current":-9.610284,"twenty":-8.191784,"median":-6.244914,"eighty":-5.018839,"marketCap":548237871},{"date":"2024-09-20","current":-9.971779,"twenty":-8.294103,"median":-6.360654,"eighty":-5.041746,"marketCap":568860105},{"date":"2024-09-27","current":-9.599714,"twenty":-8.935493,"median":-6.526024,"eighty":-5.050076,"marketCap":547634882},{"date":"2024-10-04","current":-9.037388,"twenty":-9.107996,"median":-6.621961,"eighty":-5.093809,"marketCap":515555851},{"date":"2024-10-11","current":-9.978122,"twenty":-9.382394,"median":-6.703603,"eighty":-5.220301,"marketCap":569221899},{"date":"2024-10-18","current":-10.49394,"twenty":-9.484712,"median":-6.794175,"eighty":-5.315929,"marketCap":598647777},{"date":"2024-10-25","current":-10.06691,"twenty":-9.672968,"median":-6.825412,"eighty":-5.346971,"marketCap":574287009},{"date":"2024-10-31","current":-9.792089,"twenty":-9.748541,"median":-7.119566,"eighty":-5.360507,"marketCap":558609287},{"date":"2024-11-08","current":-9.443128,"twenty":-9.802236,"median":-7.283651,"eighty":-5.372344,"marketCap":572357443},{"date":"2024-11-15","current":-7.16039,"twenty":-9.789552,"median":-7.500596,"eighty":-5.379633,"marketCap":433998376},{"date":"2024-11-22","current":-5.434099,"twenty":-9.773909,"median":-7.256318,"eighty":-5.396215,"marketCap":329366155},{"date":"2024-11-29","current":-5.407973,"twenty":-9.752346,"median":-7.139978,"eighty":-5.371303,"marketCap":327782663},{"date":"2024-12-06","current":-4.760865,"twenty":-9.734588,"median":-6.825412,"eighty":-5.339276,"marketCap":288560806},{"date":"2024-12-13","current":-0.854102,"twenty":-9.716407,"median":-6.794175,"eighty":-5.114636,"marketCap":51767979},{"date":"2024-12-20","current":-0.671224,"twenty":-9.680505,"median":-6.703603,"eighty":-5.031844,"marketCap":40683541},{"date":"2024-12-27","current":-0.719455,"twenty":-9.66543,"median":-6.637987,"eighty":-4.975898,"marketCap":43606909},{"date":"2025-01-03","current":-0.69333,"twenty":-9.621313,"median":-6.605935,"eighty":-4.929676,"marketCap":42023418},{"date":"2025-01-10","current":-0.657156,"twenty":-9.603942,"median":-6.526024,"eighty":-4.86516,"marketCap":39830892},{"date":"2025-01-17","current":-0.631031,"twenty":-9.545173,"median":-6.362567,"eighty":-4.746844,"marketCap":38247401},{"date":"2025-01-24","current":-0.677253,"twenty":-9.492745,"median":-6.288512,"eighty":-4.6939,"marketCap":41048962},{"date":"2025-01-31","current":-0.655147,"twenty":-9.465263,"median":-6.219701,"eighty":-4.511228,"marketCap":39709085},{"date":"2025-02-07","current":-0.63505,"twenty":-9.453365,"median":-6.05877,"eighty":-3.980076,"marketCap":38491015},{"date":"2025-02-14","current":-0.538587,"twenty":-9.43896,"median":-5.948893,"eighty":-0.813105,"marketCap":32644278},{"date":"2025-02-21","current":-0.488345,"twenty":-9.423405,"median":-5.89118,"eighty":-0.724279,"marketCap":29599103},{"date":"2025-02-28","current":-0.450162,"twenty":-9.384931,"median":-5.843753,"eighty":-0.704182,"marketCap":27284770},{"date":"2025-03-07","current":-0.468249,"twenty":-9.351106,"median":-5.738018,"eighty":-0.689713,"marketCap":28381033},{"date":"2025-03-14","current":-0.470191,"twenty":-9.227225,"median":-5.670316,"eighty":-0.675243,"marketCap":22443611},{"date":"2025-03-21","current":-0.53152,"twenty":-9.18875,"median":-5.509385,"eighty":-0.665195,"marketCap":25371039},{"date":"2025-03-28","current":-0.482968,"twenty":-9.161872,"median":-5.425609,"eighty":-0.655147,"marketCap":23053492},{"date":"2025-04-04","current":-0.408861,"twenty":-9.091808,"median":-5.407973,"eighty":-0.643893,"marketCap":19516184},{"date":"2025-04-11","current":-0.429305,"twenty":-9.050837,"median":-5.380674,"eighty":-0.631433,"marketCap":20491993},{"date":"2025-04-17","current":-0.472746,"twenty":-9.045443,"median":-5.362133,"eighty":-0.622992,"marketCap":22565587},{"date":"2025-04-25","current":-0.472746,"twenty":-9.037388,"median":-5.336421,"eighty":-0.57878,"marketCap":22565587},{"date":"2025-05-02","current":-0.39864,"twenty":-8.919003,"median":-5.165991,"eighty":-0.546852,"marketCap":19028279},{"date":"2025-05-09","current":-0.314156,"twenty":-8.857697,"median":-5.050076,"eighty":-0.534567,"marketCap":18784327},{"date":"2025-05-16","current":-0.354955,"twenty":-8.778159,"median":-5.035734,"eighty":-0.528965,"marketCap":21223850},{"date":"2025-05-23","current":-0.336596,"twenty":-8.694918,"median":-4.992187,"eighty":-0.51491,"marketCap":20126064},{"date":"2025-05-30","current":-0.385555,"twenty":-8.584144,"median":-4.945951,"eighty":-0.506094,"marketCap":23053492},{"date":"2025-06-06","current":-0.375355,"twenty":-8.389867,"median":-4.923647,"eighty":-0.48773,"marketCap":22443611},{"date":"2025-06-13","current":-0.346796,"twenty":-8.305941,"median":-4.87898,"eighty":-0.485012,"marketCap":20735945},{"date":"2025-06-20","current":-0.325376,"twenty":-8.294103,"median":-4.767993,"eighty":-0.472746,"marketCap":19455195},{"date":"2025-06-26","current":-0.318236,"twenty":-8.282264,"median":-4.754675,"eighty":-0.469026,"marketCap":19028279}],"updateTime":1751019299262}}}